Mandate

Vinge acted as local counsel in relation to the sale of Phadia, the biotechnology company, for SEK 22 billion

May 20, 2011

Cinven has entered into an agreement with Thermo Fisher Scientific to sell the Uppsala based biotechnology company, Phadia Group, for SEK 22 billion. Phardia is a spin-off from the former Pharmacia and enjoys a leading position within allergy testing.

Vinge acted as local counsel advising on Swedish legal issues for Cinven/Freshfields. Vinge's team consisted of partner Christina Kokko and associates Joacim Rydergård, Jonas Bergström, Alex Miller and Albert Wållgren.

Related news

Vinge advises Ramirent in connection with its acquisition of JIAB

Vinge advises Ramirent AB in connection with its acquisition of JIAB Hyrcenter (consisting of the companies JIAB Hyrcenter AB and JIAB Boden AB). Ramirent thereby further strengthens its position in Norrbotten and as the largest machine rental company in Sweden.
March 21, 2023

Vinge has advised Svea Bank AB in connection with the issuance of Additional Tier 1 Capital of SEK 300 million

Vinge has advised Svea Bank AB (the “Company”) in connection with its issuance of additional tier 1 capital (AT1) of SEK 300 million to optimise its capital structure.
March 14, 2023

Vinge advises Anglo American in connection with investment in the Dannemora mine

Vinge has, together with Norton Rose Fulbright, advised Anglo American Limited in connection with entering into a royalty agreement of USD 10 million and a binding term sheet for an offtake agreement with Dannemora Iron AB. Moreover, Vinge has assisted with thereto related due diligence. Dannemora Iron AB is a wholly owned subsidiary of Grängesberg Exploration Holding AB (publ).
March 14, 2023